ursodeoxycholic acid
Evolving the Treatment Paradigm in Second-Line Primary Biliary Cholangitis With IQIRVO (elafibranor): A First-in-Class PPAR Agonist
This Special Report discusses considerations for monitoring and treating patients with primary biliary cholangitis ...
APRIL 1, 2025
FDA Approves Seladelpar for Primary Biliary Cholangitis
The FDA has granted accelerated approval to seladelpar (Livdelzi, Gilead) in combination with ursodeoxycholic acid ...
AUGUST 21, 2024
FDA Approves Elafibranor for Primary Biliary Cholangitis
The FDA granted accelerated approval for elafibranor (Iqirvo, Ipsen), a peroxisome proliferator−activated ...
JUNE 12, 2024
Expert Picks From The Liver Meeting, Part 2
In this second installment of “Expert Picks” from The Liver Meeting 2022, Ashwani K. Singal, MD, MS, ...
APRIL 19, 2023
Load more